Global Drug Facility Update on Access to Bedaquiline

Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership's Global Drug Facility’s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB community important updates on plans to launch a global, competitive tender for bedaquiline by end July 2023. All bedaquiline suppliers that meet GDF`s quality criteria are eligible to participate in the GDF bedaquiline tender and have been briefed on the tender goals, processes, and timelines.